Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,444,450.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $573.10, for a total value of $5,444,450.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $23,218,000.30. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Down 0.6%

Shares of NASDAQ:UTHR opened at $575.79 on Friday. The company has a market cap of $24.44 billion, a PE ratio of 21.25, a P/E/G ratio of 1.83 and a beta of 0.60. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The firm has a 50-day simple moving average of $556.50 and a 200 day simple moving average of $506.65.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 earnings per share. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Royal Bank Of Canada dropped their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective on the stock. Finally, Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Trading of United Therapeutics

Large investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. Entrust Financial LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. International Assets Investment Management LLC lifted its position in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its position in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.